Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

December 17, 2010

Primary Completion Date

May 1, 2020

Study Completion Date

February 28, 2026

Conditions
Prostate Cancer
Interventions
DRUG

Bicalutamide

Bicalutamide 50 mg orally daily with either dutasteride or finasteride for 2 months. After two months of treatment bicalutamide with either dutasteride or finasteride will be taken along with radiation. After completion of radiation, bicalutamide will be stopped.

DRUG

Dutasteride

Dutasteride 0.5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment dutasteride and bicalutamide will be taken along with radiation. After completion of radiation, dutasteride will be taken alone for two years.

DRUG

Finasteride

Finasteride 5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment finasteride and bicalutamide will be taken along with radiation. After completion of radiation, finasteride will be taken alone for two years.

RADIATION

Radiation

7-8 weeks of radiation with bicalutamide and either dutasteride or finasteride.

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER